The CoMO Scientific Advisory Group (CSAG) is a reference group of medical experts and clinicians.
The group advise CoMO’s Governing Council on meningitis issues and immunisation projects across CoMO’s three regions – Americas, Asia Pacific and Europe Africa.
After qualifying in medicine, James worked as a clinical doctor in the UK and rural South Africa before specialising in public health. An infectious disease epidemiologist, James has been involved in outbreak investigation and control at an international level, and has published many papers on risk factors for meningococcal disease and carriage.
Ron has been working in the field of meningitis and meningococcal vaccines for more than 44 years. A medical advisor and consultant, Ron’s research has focused primarily on the management of bacterial meningitis and the safety and efficacy of childhood vaccines.
Catherine is Head of Paediatric Services at Hospital Louis Mourier, Professor of Paediatrics at the University of Paris VII and a medical doctor. An expert in the registration process for vaccines, antibiotics and anti-virals, Catherine is a contributor to the European Centre for Disease Prevention and Control and has previously worked on the Vaccine Working Party for Europe, the Middle East and Africa.
Priscilla is Senior Lecturer in epidemiology and public health at La Trobe University and has been involved in meningococcal disease research and public health prevention for more than 26 years.
An infectious diseases paediatrician, Robert is Head of Clinical Research at the National Centre for Immunisation Research and Surveillance (NCIRS) and a Professor at the University of Sydney. His research includes looking at the clinical, public-health, social and economic burden of diseases and the ways to prevent or control serious infections through vaccines, drugs and non-pharmaceutical measures.
Mark is Director of PATH’s pneumococcal, group B streptococcal and polyvalent meningococcal vaccine projects that seek to accelerate the development, licensure and availability of promising new vaccines for use in low-income settings. Mark is an immunologist with more than 30 years of experience in medical research, biotechnology, pharmaceuticals and vaccine development.